Filing Flows › Arcutis Biotherapeutics (ARQT) › Q2 2026
Arcutis Biotherapeutics (ARQT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Arcutis Biotherapeutics (ARQT) reported revenue of $130M for the second quarter 2026 (Q2 2026), +59% from a year earlier and +23% from the quarter before. Operating margin was 12.7%, net earnings $15.0M (11.6% of revenue).
Arcutis Biotherapeutics, Q2 2026: revenue $130M (+59% year over year), operating margin 12.7%, net earnings $15.0M, operating cash flow $12.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $130M | +23% | +59% |
| Operating profit | $16.4M | — | — |
| Net earnings | $15.0M | — | — |
| Operating cash flow | $12.6M | +464% | 39× |
| Free cash flow | $12.5M | +457% | 51× |
What changed
Revenue was $129.9M in Q2 2026, up 59% year over year and up 23% from the previous quarter. ZORYVE foam was the largest line at 52% of revenue. ZORYVE foam added $28.2M year over year (up 72%), 58% of the total change.
Operating profit was $16.4M, a 12.7% margin (up 30.6 points year over year). Total costs grew 18% against revenue growth of 59%. The fastest-growing cost line was Cost of revenue (+46%). Net earnings were $15.0M. The effective tax rate was 0.9%.
Operating cash flow was $12.6M (up 3801% year over year), 84% of net earnings. Non-cash charges added back $12.8M of share-based compensation. Working capital and other items used $15.1M. Capital expenditures of $158K left free cash flow of $12.5M.
Questions
What was Arcutis Biotherapeutics' revenue in the second quarter 2026?
Arcutis Biotherapeutics (ARQT) reported revenue of $130M for the second quarter 2026 (Q2 2026), +59% from a year earlier and +23% from the quarter before.
Was Arcutis Biotherapeutics profitable in the second quarter 2026?
Operating profit was $16.4M (12.7% of revenue) and net earnings $15.0M.